|
KR100513062B1
(ko)
*
|
1998-04-03 |
2005-09-05 |
가부시키 가이샤 오오쯔카 세이야쿠 고우죠우 |
트리아조로푸린 유도체, 그 유도체를 함유하는 의약조성물, 아데노신 에이3 수용체 친화제 및 천식치료제
|
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
|
YU76100A
(sh)
*
|
1998-06-02 |
2003-12-31 |
Osi Pharmaceuticals Inc. |
Pirolo(2,3-d) pirimidin preparati i njihova primena
|
|
US6921825B2
(en)
|
1998-09-16 |
2005-07-26 |
King Pharmaceuticuals Research & Development, Inc. |
Adenosine A3 receptor modulators
|
|
US6448253B1
(en)
*
|
1998-09-16 |
2002-09-10 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A3 receptor modulators
|
|
WO2001023391A1
(en)
*
|
1999-09-28 |
2001-04-05 |
Otsuka Pharmaceutical Factory, Inc. |
Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents
|
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
KR100840727B1
(ko)
|
1999-12-02 |
2008-06-23 |
오에스아이 파마슈티컬스, 인코포레이티드 |
아데노신 a1, a2a 및 a3 수용체 특이 화합물 및 그의 사용방법
|
|
SI1283839T1
(da)
|
2000-05-26 |
2005-08-31 |
Schering Corp |
|
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
US6680324B2
(en)
*
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
GB0100624D0
(en)
*
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
|
EP1425017A1
(en)
*
|
2001-09-13 |
2004-06-09 |
Schering Corporation |
Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
|
|
JP4545437B2
(ja)
|
2001-10-15 |
2010-09-15 |
シェーリング コーポレイション |
アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
AU2002360436A1
(en)
|
2001-11-30 |
2003-06-17 |
Osi Pharmaceuticals, Inc. |
2-aryl pyrrologpyrimidines for a1 and a3 receptors
|
|
CA2468649C
(en)
|
2001-11-30 |
2009-03-10 |
Schering Corporation |
Adenosine a2a receptor antagonists
|
|
ES2283625T3
(es)
|
2001-11-30 |
2007-11-01 |
Schering Corporation |
Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.
|
|
CN101973998A
(zh)
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
|
CN1620294A
(zh)
|
2001-12-20 |
2005-05-25 |
Osi药物公司 |
嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
|
|
MXPA03008967A
(es)
*
|
2002-02-01 |
2004-02-12 |
King Pharmaceuticals Res & Dev |
Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
|
|
IL160133A0
(en)
*
|
2002-05-30 |
2004-06-20 |
King Pharmaceuticals Res & Dev |
Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
|
|
JP2006514697A
(ja)
|
2002-12-19 |
2006-05-11 |
シェーリング コーポレイション |
アデノシンA2aレセプターアンタゴニストの使用
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
CL2004000847A1
(es)
|
2003-04-23 |
2005-03-11 |
Schering Corp |
Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion,
|
|
EP1745047B1
(en)
|
2004-04-21 |
2010-03-24 |
Schering Corporation |
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
|
|
ATE538123T1
(de)
|
2005-09-19 |
2012-01-15 |
Schering Corp |
2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
JP5453086B2
(ja)
|
2006-06-06 |
2014-03-26 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
|
US7691869B2
(en)
|
2007-03-30 |
2010-04-06 |
King Pharmaceuticals Research And Development, Inc. |
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
|
|
ES2588238T3
(es)
|
2007-12-06 |
2016-10-31 |
Intra-Cellular Therapies, Inc. |
Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
|
|
EP2262811B1
(en)
|
2008-03-04 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
|
KR20110098732A
(ko)
|
2008-12-06 |
2011-09-01 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
|
AU2009322904A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2010065147A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
US9434730B2
(en)
|
2010-05-31 |
2016-09-06 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
|
WO2011153135A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CN103261202B
(zh)
*
|
2010-09-24 |
2016-01-20 |
阿迪维纳斯疗法有限公司 |
作为腺苷受体拮抗剂的稠合三环化合物
|
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CA2967944C
(en)
|
2014-11-18 |
2020-11-17 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
|
US10688082B2
(en)
|
2015-06-11 |
2020-06-23 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with A2A antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
EP3723754A4
(en)
|
2017-12-13 |
2021-05-19 |
Merck Sharp & Dohme Corp. |
IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
CN111072676B
(zh)
*
|
2019-12-12 |
2021-07-16 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|